Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pacific Biosciences (PACB)

Pacific Biosciences (PACB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 546,941
  • Shares Outstanding, K 154,068
  • Annual Sales, $ 90,890 K
  • Annual Income, $ -84,130 K
  • 60-Month Beta 1.68
  • Price/Sales 5.97
  • Price/Cash Flow N/A
  • Price/Book 8.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.19
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.23
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.16 +15.66%
on 05/05/20
3.80 -3.82%
on 05/22/20
+0.39 (+12.12%)
since 05/01/20
3-Month
2.20 +66.14%
on 03/18/20
4.06 -9.98%
on 03/04/20
+0.21 (+6.25%)
since 03/02/20
52-Week
2.20 +66.14%
on 03/18/20
7.03 -48.01%
on 06/05/19
-3.04 (-45.45%)
since 05/31/19

Most Recent Stories

More News
Personal Genomics, Inc. Files Patent Infringement Complaint Against Pacific Biosciences of California, Inc. in China

HSINCHU, , /PRNewswire/ -- Personal Genomics Taiwan, Inc. ("PGI"), today announced that it has filed a patent infringement complaint in the Wuhan People's Court in against Pacific Biosciences of , Inc....

PACB : 3.66 (+3.10%)
Allscripts Unit Inks Deal to Boost Veradigm AccelRx Platform

This deal is expected to bolster Allscripts' (MDRX) Clinical and Financial Solutions segment.

MDRX : 6.59 (+0.15%)
DXCM : 374.31 (-1.16%)
PACB : 3.66 (+3.10%)
APHA : 4.46 (+0.45%)
Here's Why You Should Retain Masimo Stock (MASI) For Now

Investor confidence remains high in Masimo (MASI) stock, thanks to solid prospects.

MASI : 232.66 (-1.81%)
DXCM : 374.31 (-1.16%)
PACB : 3.66 (+3.10%)
APHA : 4.46 (+0.45%)
Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates

Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.

BIIB : 302.20 (+0.25%)
LLY : 152.25 (-0.13%)
PACB : 3.66 (+3.10%)
APHA : 4.46 (+0.45%)
Pacific Biosciences: 1Q Earnings Snapshot

MENLO PARK, Calif. (AP) _ Pacific Biosciences of California Inc. (PACB) on Wednesday reported first-quarter net income of $1.3 million, after reporting a loss in the same period a year earlier.

PACB : 3.66 (+3.10%)
Pacific Biosciences of California, Inc. Announces First Quarter 2020 Financial Results

Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its first quarter ended March 31, 2020.

PACB : 3.66 (+3.10%)
Varian (VAR) Earnings and Revenues Surpass Estimates in Q2

Varian (VAR) continued to gain from core Oncology Systems segment in Q2.

VAR : 123.33 (+0.64%)
EXAS : 85.69 (+0.37%)
PACB : 3.66 (+3.10%)
APHA : 4.46 (+0.45%)
Luminex (LMNX) Q1 Earnings Miss Estimates, Revenues Beat

Luminex's (LMNX) first-quarter earnings benefit from solid performance across Consumable Sales, Assay, Service and Other Revenues.

LMNX : 30.31 (-4.23%)
EXAS : 85.69 (+0.37%)
PACB : 3.66 (+3.10%)
APHA : 4.46 (+0.45%)
CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates

CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.

CNMD : 74.20 (+0.35%)
EXAS : 85.69 (+0.37%)
PACB : 3.66 (+3.10%)
APHA : 4.46 (+0.45%)
PRA Health (PRAH) Q1 Earnings and Revenues Beat Estimates

PRA Health's (PRAH) Clinical Research segment puts up a strong performance in Q1.

EXAS : 85.69 (+0.37%)
PRAH : 105.04 (+1.68%)
PACB : 3.66 (+3.10%)
APHA : 4.46 (+0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade PACB with:

Business Summary

Pacific Biosciences of California, Inc. is engaged in the development, manufacture and commercialization of its single molecule, real-time, or SMRT technology-an integrated platform for genetic analysis. The SMRT technology uses the natural processing power of enzymes, combined with specially designed...

See More

Key Turning Points

2nd Resistance Point 3.65
1st Resistance Point 3.60
Last Price 3.66
1st Support Level 3.50
2nd Support Level 3.46

See More

52-Week High 7.03
Fibonacci 61.8% 5.18
Fibonacci 50% 4.62
Fibonacci 38.2% 4.05
Last Price 3.66
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar